1. Sequence-dependent cross-resistance of combined radiotherapy plus BRAF
- Author
-
B, Shannan, J, Matschke, H, Chauvistré, F, Vogel, D, Klein, F, Meier, D, Westphal, J, Bruns, R, Rauschenberg, J, Utikal, A, Forschner, C, Berking, P, Terheyden, E, Dabrowski, R, Gutzmer, D, Rafei-Shamsabadi, F, Meiss, L, Heinzerling, L, Zimmer, Elisabeth, Livingstone, Renáta, Váraljai, A, Hoewner, S, Horn, J, Klode, M, Stuschke, B, Scheffler, A, Marchetto, G, Sannino, T G P, Grünewald, D, Schadendorf, V, Jendrossek, and A, Roesch
- Subjects
Adult ,Male ,Proto-Oncogene Proteins B-raf ,MAP Kinase Signaling System ,Apoptosis ,Radiation Tolerance ,Cell Movement ,Tumor Cells, Cultured ,Humans ,Melanoma ,Protein Kinase Inhibitors ,Aged ,Cell Proliferation ,Retrospective Studies ,Aged, 80 and over ,Radiotherapy ,Brain Neoplasms ,Cell Cycle ,Chemoradiotherapy ,Middle Aged ,Prognosis ,Xenograft Model Antitumor Assays ,Drug Resistance, Neoplasm ,Mutation ,Female ,Follow-Up Studies - Abstract
Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common.Our preclinical models indicated a higher rate of tumour relapse when melanoma cells were first treated with BRAFThe level of cross-resistance between combined MAPK inhibition and radiotherapy is dependent on the treatment sequence. JARID1B may represent a novel therapy-overarching resistance marker.
- Published
- 2018